TIBET PHARMA(SH:600211) Xin Lang Cai Jing·2025-11-07 05:35Group 1 - The core point of the article highlights the recent performance of Tibet Pharmaceutical, which saw a 5.13% increase in stock price, reaching 47.12 CNY per share, with a trading volume of 238 million CNY and a turnover rate of 1.61%, resulting in a total market capitalization of 15.188 billion CNY [1] - Tibet Pharmaceutical, officially known as Tibet Nodi Kang Pharmaceutical Co., Ltd., is located in Lhasa Economic and Technological Development Zone and was established on July 14, 1999. The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales and 0.20% from other sources [1] Group 2 - From the perspective of fund holdings, data indicates that one fund under Chuangjin Hexin has a significant position in Tibet Pharmaceutical. The Chuangjin Hexin ESG Responsibility Investment Stock A (011149) held 22,500 shares in the third quarter, accounting for 2.49% of the fund's net value, making it the eighth largest holding. The estimated floating profit for today is approximately 51,700 CNY [2] - The Chuangjin Hexin ESG Responsibility Investment Stock A (011149) was established on December 30, 2020, with a latest scale of 21.7358 million CNY. Year-to-date returns stand at 23.35%, ranking 2503 out of 4216 in its category, while the one-year return is 13.54%, ranking 2934 out of 3913. Since inception, the fund has achieved a return of 18.47% [2] Group 3 - The fund managers of Chuangjin Hexin ESG Responsibility Investment Stock A (011149) are Gong Chao and Wang Xin. As of the report, Gong Chao has been in position for 4 years and 225 days, managing a total fund size of 168 million CNY, with the best return during his tenure being 15.27% and the worst being -24.28% [3] - Wang Xin has been in position for 4 years and 313 days, overseeing a total fund size of 428 million CNY, with the best return during his tenure being 25.06% and the worst being -16.16% [3]